ArticleAmerican journal of respiratory cell and molecular biology2018
Targeting Intracellular Ion Homeostasis for the Control of Respiratory Syncytial Virus.
Article in American journal of respiratory cell and molecular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- B-Raf kinase blockade protects airway epithelial cells against respiratory syncytial virus infection and modulates interferon responses.ERJ open research · 2025Article
- New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders.World journal of gastroenterology · 2023Review
- Statin-mediated disruption of Rho GTPase prenylation and activity inhibits respiratory syncytial virus infection.Communications biology · 2021Article
- Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses.Molecules (Basel, Switzerland) · 2021Review
- Inflammatory epithelial cytokines afterERJ open research · 2021Article
- The Nonribosomal Peptide Valinomycin: From Discovery to Bioactivity and Biosynthesis.Microorganisms · 2021Review
- NaFrontiers in pharmacology · 2021Review
- Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.Frontiers in pharmacology · 2021Review
- Semisynthetic Cardenolides Acting as Antiviral Inhibitors of Influenza A Virus Replication by Preventing Polymerase Complex Formation.Molecules (Basel, Switzerland) · 2020Article
- Valinomycin as a potential antiviral agent against coronaviruses: A review.Biomedical journal · 2020Review
- Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.Scientific reports · 2020Article
- Article
- Elucidation of the mechanism of anti-herpes action of two novel semisynthetic cardenolide derivatives.Archives of virology · 2020Article
- Novel Ionophores Active against La Crosse Virus Identified through Rapid Antiviral Screening.Antimicrobial agents and chemotherapy · 2020Article
- Alphavirus Replication: The Role of Cardiac Glycosides and Ion Concentration in Host Cells.BioMed research international · 2020Review
- A Nonhospitable Host: Targeting Cellular Factors as an Antiviral Strategy for Respiratory Viruses.American journal of respiratory cell and molecular biology · 2018Article
- Light Up the COVID-19.Journal of medical signals and sensorsArticle
- Nonredundant roles of DIAPHs in primary ciliogenesis.The Journal of biological chemistryArticle
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a leading cause of mortality in infants and young children. Despite the RSV disease burden, no vaccine is available, and treatment remains nonspecific. New drug candidates are needed to combat RSV. Toward this goal, we screened over 2,000 compounds to identify approved drugs with novel anti-RSV activity. Cardiac glycosides, inhibitors of the membrane-bound Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.